Edward Cliff: POLARIX trial of antibody-drug conjugate polatuzumab vedotin in diffuse large B-cell lymphoma.

Edward Cliff, Postdoctoral Research Fellow at Harvard Medical School, shared on LinkedIn:

“Just out in Blood: David Russler-Germain, Nancy Bartlett and I delve into the cell of origin subgroup analysis from the POLARIX trial of antibody-drug conjugate polatuzumab vedotin in diffuse large B-cell lymphoma, and explain why we think this signal is confirmatory rather than hypothesis-generating.

We highlight the pre-clinical, observational and clinical trial evidence all points to the same pattern: polatuzumab seems to work better in ABC-type Diffuse Large B-Cell Lymphoma.”

To read the paper click here.
Source: Edward Cliff/LinkedIn